Protagonist ( PTGX ) Q2 Revenue Falls 26%
Protagonist Therapeutics ( NASDAQ:PTGX ) , a clinical-stage biotechnology company developing peptide-based therapies for blood and immune diseases, released second quarter results on August 6, 2025. The most significant news from the release was the company's continued advancement of its ...
Protagonist Therapeutics ( PTGX ) Reports Q2 Loss, Lags Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.77% and -46.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.
Tango Therapeutics ( TNGX ) Moves 7.5% Higher: Will This Strength Last?
Tango Therapeutics (TNGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
Data from a late-stage study shows that treatment with JNJ's icotrokinra helps achieve significant skin clearance in hard-to-treat scalp and genital psoriasis.
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study - Protagonist Therapeutics ( NASDAQ:PTGX ) , Johnson & Johnson ( NYSE:JNJ )
77% of genital psoriasis patients saw clear/almost clear skin vs. 21% on placebo after 16 weeks. PN-881 showed 70x greater potency than secukinumab in vitro and effective reduction in skin inflammation in rat models.
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demonstrate a standout combination of significant skin clearance ( IGA 0/1 ) and a favorable safety ...
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders - Keros Therapeutics ( NASDAQ:KROS )
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth
Protagonist Therapeutics ( PTGX ) Reports Q1 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 62% and 149.90%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Johnson & Johnson Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Johnson & Johnson ( NYSE:JNJ )
Johnson & Johnson JNJ will release earnings results for the first quarter, before the opening bell on Tuesday, April 15. Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.58 per share, down from $2.71 per share in the year-ago period.
Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study - Protagonist Therapeutics ( NASDAQ:PTGX ) , Johnson & Johnson ( NYSE:JNJ )
84.1% of adolescents on icotrokinra achieved clear/almost clear skin at Week 16 vs. 27.3% on placebo in Phase 3 PsO study. By Week 24, 75% of adolescents on icotrokinra had completely clear skin ( IGA 0 ) , with no new safety issues reported.
Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics ( PTGX ) : Can the Stock Really Move This High?
The consensus price target hints at a 27.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week ( Mar 10-Mar 14 ) : Are The Others In Your Portfolio? - D-Wave Quantum ( NYSE:QBTS ) , IonQ ( NYSE:IONQ )
D-Wave Quantum soared 95.95% on a 502% YoY increase in Q4 bookings to $18.3M. Protagonist Therapeutics jumped 42.84% after its Phase 2b ANTHEM-UC study met primary endpoints. Next: Get access to a new market-moving chart every day featuring a stock flashing clear technical signals.
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
Novo Nordisk, Roche, Pfizer, Arvinas and J&J are part of the Zacks top Analyst Blog.
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More
TSVT and PTGX are in the spotlight this week following an acquisition agreement and study data, respectively.
Protagonist Therapeutics ( PTGX ) Upgraded to Buy: Here's Why
Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Asana ( NYSE:ASAN ) , AvePoint ( NASDAQ:AVPT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Citigroup cut AvePoint, Inc. AVPT price target from $18 to $16. Citigroup analyst Fatima Boolani maintained ...
Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday - The Campbell's ( NASDAQ:CPB ) , Archer-Daniels Midland ( NYSE:ADM )
U.S. stocks were lower, with the Nasdaq Composite falling around 650 points on Monday. Shares of Redfin Corporation RDFN rose sharply during Monday's session after Rocket Companies announced it will acquire the company in an all-stock transaction valued at $12.50 per share.
Why Is Protagonist Therapeutics Stock Trading Higher On Monday? - Protagonist Therapeutics ( NASDAQ:PTGX ) , Johnson & Johnson ( NYSE:JNJ )
In the ANTHEM-UC study, 63.5% of patients on the highest icotrokinra dose achieved a clinical response at Week 12 vs. 27.0% on placebo. In the ICONIC-LEAD study, 65% of icotrokinra-treated psoriasis patients achieved clear or almost clear skin vs. 8% on placebo at Week 16.
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer - Protagonist Therapeutics ( NASDAQ:PTGX ) , Takeda Pharmaceutical Co ( NYSE:TAK )
77% of rusfertide patients achieved response vs. 33% on placebo at weeks 20-32. Rusfertide patients had 0.5 phlebotomies vs. 1.8 in the placebo group over 32 weeks. Our government trade tracker caught Pelosi's 169% AI winner. Discover how to track all 535 Congress member stock trades today.
Protagonist Therapeutics ( PTGX ) Tops Q4 Earnings and Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 3,200% and 202.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday - Atkore ( NYSE:ATKR ) , Carpenter Tech ( NYSE:CRS )
U.S. stocks were mixed, with the Dow Jones index gaining more than 150 points on Friday. Shares of Natural Grocers by Vitamin Cottage, Inc. NGVC rose sharply during Friday's session following quarterly results.
Protagonist Therapeutics ( PTGX ) Upgraded to Buy: Here's What You Should Know
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Protagonist Therapeutics ( PTGX ) Reports Q3 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 8.47% and 3.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Peptide Therapeutics Market to Witness 5.94% CAGR by 2031 | SkyQuest Technology
Westford, USA, Sept. 27, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that Peptide Therapeutics Market will attain the value of USD 68.4 Billion by 2031, with a CAGR of 5.94% during the forecast period ( 2024-2031 ) .
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines - Protagonist Therapeutics ( NASDAQ:PTGX )
Truist Securities initiated coverage on Protagonist Therapeutics Inc PTGX, citing its first-in-class lead asset with encouraging Phase 2 data in a rare form of blood cancer and a multi-billion dollar opportunity.
Protagonist Therapeutics ( PTGX ) Reports Q2 Loss, Misses Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 0% and 89.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
AT&T, Group 1 Automotive, Mattel, Seagate And Other Big Stocks Moving Higher On Wednesday - Alkermes ( NASDAQ:ALKS ) , Avantor ( NYSE:AVTR )
U.S. stocks were lower, with the Dow Jones index falling around 350 points on Wednesday. Shares of AT&T Inc. T rose during Wednesday's session following second-quarter earnings.
Protagonist Therapeutics ( PTGX ) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Protagonist Therapeutics (PTGX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Protagonist Therapeutics Shows Market Leadership With Jump To 92 RS Rating
On Thursday, Protagonist Therapeutics ( PTGX ) hit an important technical milestone, with its Relative Strength ( RS ) Rating moving into the 90-plus percentile with an improvement to 92, an increase from 85 the day before. X IBD's proprietary rating measures market leadership with a 1 ( ...
Protagonist Therapeutics Shows Market Leadership With Jump To 87 RS Rating
Protagonist Therapeutics ( PTGX ) had its Relative Strength ( RS ) Rating upgraded from 80 to 87 Tuesday. X IBD's proprietary rating measures market leadership with a 1 ( worst ) to 99 ( best ) score. The grade shows how a stock's price behavior over the last 52 weeks stacks up against all ...
Nurix Therapeutics Appoints Paula G. O'Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer
Expanded C-level team poised to accelerate development of NX-5948 in B cell malignancies Expanded C-level team poised to accelerate development of NX-5948 in B cell malignancies ...
Nurix Therapeutics Appoints Paula G. O'Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer - Nurix Therapeutics ( NASDAQ:NRIX )
SAN FRANCISCO, May 28, 2024 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. NRIX, a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointments of Paula G.
Protagonist Therapeutics Shows Market Leadership With Jump To 93 RS Rating
Protagonist Therapeutics ( PTGX ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Thursday, rising from 90 to 93. X This exclusive rating from Investor's Business Daily identifies market leadership with a 1 ( worst ) to 99 ( best ) score.
ProKidney Reports Business Updates and First Quarter 2024 Financial Results - ProKidney ( NASDAQ:PROK )
Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association ( ERA ) Congress on May 25, 2024. An investor call to provide a perspective on CKD with Dr. Arnold Silva and Dr. Steven Coca and a recap of the RMCL-002 data is ...
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
WINSTON-SALEM, N.C., May 10, 2024 ( GLOBE NEWSWIRE ) -- ProKidney Corp. ( Nasdaq: PROK ) ( "ProKidney" or the "Company" ) , a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease ( CKD ) , today reported business updates and financial results for the first ...
All You Need to Know About Protagonist Therapeutics ( PTGX ) Rating Upgrade to Buy
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
Dr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of cell therapies ...
Wall Street Analysts Think Protagonist Therapeutics ( PTGX ) Could Surge 48.38%: Read This Before Placing a Bet
The consensus price target hints at a 48.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
4 Stocks to Buy for Attractive Earnings Acceleration
Invest in stocks such as Protagonist Therapeutics (PTGX), Evolus (EOLS), Western Digital (WDC), and Phunware (PHUN) as of now for superb earnings acceleration.
New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year
New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in ... PR ...
4 Must-Buy Stocks for Remarkable Earnings Acceleration
Some of the notable companies to have witnessed solid earnings acceleration as of now are Protagonist Therapeutics (PTGX), AxoGen (AXGN), Western Digital (WDC) and Phunware (PHUN).
Earnings Estimates Moving Higher for Protagonist Therapeutics ( PTGX ) : Time to Buy?
Protagonist Therapeutics (PTGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics ( PTGX ) is a Great Choice
Does Protagonist Therapeutics (PTGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Protagonist Therapeutics ( PTGX ) Upgraded to Buy: What Does It Mean for the Stock?
Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Protagonist Therapeutics ( PTGX ) Could Rally 37.16%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 37.2% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Recent Price Trend in Protagonist Therapeutics ( PTGX ) is Your Friend, Here's Why
Protagonist Therapeutics (PTGX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Protagonist Therapeutics ( NASDAQ:PTGX ) Stock Rating Upgraded by StockNews.com
Protagonist Therapeutics ( NASDAQ:PTGX ) Stock Rating Upgraded by ...
